Ngā hua rapu - Anna M. Varghese

Whakamahine hua
  1. 1
    Chemotherapy for Stage II Colon Cancer

    Chemotherapy for Stage II Colon Cancer mā Anna M. Varghese

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    CAR T‐cell therapy for pancreatic cancer

    CAR T‐cell therapy for pancreatic cancer mā Carl J. DeSelm, Zachary E. Tano, Anna M. Varghese, Prasad S. Adusumilli

    I whakaputaina 2017
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Response to Erlotinib in Patients with <i>EGFR</i> Mutant Advanced Non–Small Cell Lung Cancers with a Squamous or Squamous-like Component

    Response to Erlotinib in Patients with <i>EGFR</i> Mutant Advanced Non–Small Cell Lung Cancers with a Squamous or Squamous-like Component mā Paul K. Paik, Anna M. Varghese, Camelia S. Sima, André L. Moreira, Marc Ladanyi, Mark G. Kris, Natasha Rekhtman

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m<sup>2</sup>/min

    Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m<sup>2</sup>/min mā Andrea Cercek, Vivian Park, Rona Yaeger, Diane Reidy‐Lagunes, Nancy E. Kemeny, Zsofia K. Stadler, Neil H. Segal, Anna M. Varghese, Leonard B. Saltz

    I whakaputaina 2016
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer

    A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer mā Johanna C. Bendell, Anna M. Varghese, David M. Hyman, Todd M. Bauer, Shubham Pant, Sophie Callies, Ji Lin, Ricardo Martínez, Enaksha Wickremsinhe, Aaron Alan Fink, Volker Wacheck, Kathleen N. Moore

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

    Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience mā Danielle Glassman, Randze Lerie D. Palmaira, Christina M. Covington, Avni M. Desai, Geoffrey Y. Ku, Jia Li, James J. Harding, Anna M. Varghese, Eileen M. O’Reilly, Kenneth H. Yu

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data

    Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data mā Madison Darmofal, Shalabh Suman, Gurnit Atwal, Michael Toomey, Jie‐Fu Chen, Jason C. Chang, Efsevia Vakiani, Anna M. Varghese, Anoop Balakrishnan Rema, Aijazuddin Syed, Nikolaus Schultz, Michael F. Berger, Quaid Morris

    I whakaputaina 2024
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes

    Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes mā Anna M. Varghese, Maureen F. Zakowski, Helena A. Yu, Helen Won, Gregory J. Riely, Lee M. Krug, Mark G. Kris, Natasha Rekhtman, Marc Ladanyi, Lu Wang, Michael F. Berger, M. Catherine Pietanza

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer

    Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer mā Alice T. Shaw, Anna M. Varghese, Benjamin Solomon, Daniel B. Costa, Silvia Novello, Mari Mino‐Kenudson, Mark M. Awad, Jeffrey A. Engelman, Gregory J. Riely, Valentina Monica, B.Y. Yeap, Giorgio V. Scagliotti

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations

    Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations mā Anna M. Varghese, Juber Patel, Yelena Y. Janjigian, Fanli Meng, S. Duygu Selçuklu, Gopa Iyer, Brian Houck‐Loomis, James J. Harding, Eileen M. O’Reilly, Ghassan K. Abou‐Alfa, Maeve A. Lowery, Michael F. Berger

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Clinical and molecular characterization of patients with cancer of unknown primary in the modern era

    Clinical and molecular characterization of patients with cancer of unknown primary in the modern era mā Anna M. Varghese, Arshi Arora, Marinela Capanu, Niedzica Camacho, Helen Won, Ahmet Zehir, Jianjiong Gao, Debyani Chakravarty, Nikolaus Schultz, David S. Klimstra, Marc Ladanyi, David M. Hyman, David B. Solit, Michael F. Berger, Leonard B. Saltz

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma

    Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma mā Akimasa Hayashi, Aslihan Yavas, Caitlin A. McIntyre, Yu-Jui Ho, Amanda Erakky, Winston Wong, Anna M. Varghese, Jerry P. Melchor, Michael Overholtzer, Eileen M. O’Reilly, David S. Klimstra, Olca Baştürk, Christine A. Iacobuzio‐Donahue

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer

    A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer mā M. Catherine Pietanza, Anya M. Litvak, Anna M. Varghese, Lee M. Krug, Martin Fleisher, Jerrold B. Teitcher, Andrei I. Holodny, Cami S. Sima, Kaitlin M. Woo, Kenneth Ng, Helen Won, Michael F. Berger, Mark G. Kris, Charles M. Rudin

    I whakaputaina 2016
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer

    Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer mā Marsha Reyngold, Eileen M. O’Reilly, Anna M. Varghese, Megan Fiasconaro, Melissa Zinovoy, Paul B. Romesser, Abraham J. Wu, Carla Hajj, John Cuaron, Richard Tuli, Lara Hilal, Danny N. Khalil, Wungki Park, Ellen Yorke, Zhigang Zhang, Kenneth H. Yu, Christopher H. Crane

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    <i>ALK</i> Rearrangements Are Mutually Exclusive with Mutations in <i>EGFR</i> or <i>KRAS</i>: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

    <i>ALK</i> Rearrangements Are Mutually Exclusive with Mutations in <i>EGFR</i> or <i>KRAS</i>: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer mā Justin F. Gainor, Anna M. Varghese, Sai‐Hong Ignatius Ou, Sheheryar Kabraji, Mark M. Awad, Ryohei Katayama, Amanda C. Pawlak, Mari Mino‐Kenudson, Beow Y. Yeap, Gregory J. Riely, A. John Iafrate, Maria E. Arcila, Marc Ladanyi, Jeffrey A. Engelman, Dora Dias‐Santagata, Alice T. Shaw

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

    Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer mā Davide Melisi, Do‐Youn Oh, Antoine Hollebecque, Emiliano Calvo, Anna M. Varghese, Erkut Borazanci, Teresa Macarulla, Valeria Merz, Camilla Zecchetto, Yumin Zhao, Ivelina Gueorguieva, Michael Man, Leena Gandhi, Shawn T. Estrem, Karim A. Benhadji, Mark C. Lanasa, Emin Avşar, Susan C. Guba, Rocio García‐Carbonero

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes

    Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes mā Winston Wong, Maeve A. Lowery, Michael F. Berger, Yelena Kemel, Barry S. Taylor, Ahmet Zehir, Preethi Srinivasan, Chaitanya Bandlamudi, Joanne F. Chou, Marinela Capanu, Anna M. Varghese, Kenneth H. Yu, Christine A. Iacobuzio‐Donahue, Jinru Shia, David S. Klimstra, William R. Jarnagin, Zsofia K. Stadler, Eileen M. O’Reilly

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations

    Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations mā Zishuo I. Hu, Jinru Shia, Zsofia K. Stadler, Anna M. Varghese, Marinela Capanu, Erin Salo‐Mullen, Maeve A. Lowery, Luis A. Díaz, Diana Mandelker, Kenneth H. Yu, Alice Zervoudakis, David P. Kelsen, Christine A. Iacobuzio‐Donahue, David S. Klimstra, Leonard B. Saltz, İbrahim Halil Şahin, Eileen M. O’Reilly

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma

    Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma mā Brett L. Ecker, Alice Tao, Quisette P. Janssen, Henry Walch, Colin M. Court, Vinod P. Balachandran, Christopher H. Crane, Michael I. D’Angelica, Jeffrey A. Drebin, T. Peter Kingham, Kevin C. Soares, Christine A. Iacobuzio‐Donahue, Efsevia Vakiani, Mithat Gönen, Eileen M. O’Reilly, Anna M. Varghese, William R. Jarnagin, Alice C. Wei

    I whakaputaina 2023
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes

    Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes mā Anna M. Varghese, Isha Singh, Ritu Singh, Siddharth Kunte, Joanne F. Chou, Marinela Capanu, Winston Wong, Maeve A. Lowery, Zsofia K. Stadler, Erin Salo‐Mullen, Lily V. Saadat, Alice C. Wei, Marsha Reyngold, Olca Baştürk, Ryma Benayed, Diana Mandelker, Christine A. Iacobuzio‐Donahue, David P. Kelsen, Wungki Park, Kenneth H. Yu, Eileen M. O’Reilly

    I whakaputaina 2021
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: